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Summary
Co-existence of craniopharyngioma and acromegaly has been very rarely reported. A 65-year-old man presented with 
visual deterioration, fatigue and frontal headaches. Magnetic resonance imaging revealed a suprasellar heterogeneous, 
mainly cystic, 1.9 × 2 × 1.9 cm mass compressing the optic chiasm and expanding to the third ventricle; the findings 
were consistent with a craniopharyngioma. Pituitary hormone profile showed hypogonadotropic hypogonadism, 
mildly elevated prolactin, increased insulin-like growth factor 1 (IGF-1) and normal thyroid function and cortisol 
reserve. The patient had transsphenoidal surgery and pathology of the specimen was diagnostic of adamantinomatous 
craniopharyngioma. Post-operatively, he had diabetes insipidus, hypogonadotropic hypogonadism and 
adrenocorticotropic hormone and thyroid-stimulating hormone deficiency. Despite the hypopituitarism, his IGF-1 levels 
remained elevated and subsequent oral glucose tolerance test did not show complete growth hormone (GH) suppression. 
Further review of the pre-operative imaging revealed a 12 × 4 mm pituitary adenoma close to the right carotid artery and 
no signs of pituitary hyperplasia. At that time, he was also diagnosed with squamous cell carcinoma of the left upper 
lung lobe finally managed with radical radiotherapy. Treatment with long-acting somatostatin analogue was initiated 
leading to biochemical control of the acromegaly. Latest imaging has shown no evidence of craniopharyngioma regrowth 
and stable adenoma. This is a unique case report of co-existence of craniopharyngioma, acromegaly and squamous lung 
cell carcinoma that highlights diagnostic and management challenges. Potential effects of the GH hypersecretion on the 
co-existent tumours of this patient are also briefly discussed.
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Learning points:
 • Although an extremely rare clinical scenario, craniopharyngioma and acromegaly can co-exist; aetiopathogenic 
link between these two conditions is unlikely.
 • Meticulous review of unexpected biochemical findings is vital for correct diagnosis of dual pituitary pathology.
 • The potential adverse impact of GH excess due to acromegaly in a patient with craniopharyngioma (and other 
neoplasm) mandates adequate biochemical control of the GH hypersecretion.
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Background
Craniopharyngiomas are rare benign epithelial sellar/
parasellar tumours with annual incidence of 0.13–0.20 
cases/100 000 (1, 2). They can be detected at any age (from 
the prenatal and neonatal period until late adulthood) and 
are associated with significant morbidity and mortality 
making them one of the most challenging tumours to 
manage (2). Acromegaly is also a rare condition with 
prevalence of 2.8–13.7 cases/100 000 people and annual 
incidence of 0.2–1.1 cases/100 000 (3).
Co-existence of a craniopharyngioma with pituitary 
adenomas or other (para)sellar tumours has been rarely 
described.
Herein, we present a challenging case of a patient 
with a craniopharyngioma co-existent with acromegaly 
who during the pre-operative assessment for the removal 
of the craniopharyngioma was also diagnosed with 
squamous cell lung carcinoma.
Case presentation
A 65-year-old man presented with a three-month history 
of visual deterioration, fatigue and frontal headaches. His 
medical history included hypertension. He was a smoker 
(55  pack-years). Ophthalmological assessment revealed 
right optic neuropathy, decreased visual acuity (right 
and left eye 6/60 and 6/9, respectively) and defects in 
both temporal fields, as well as in the right nasal field. 
Subsequent head magnetic resonance imaging (MRI) 
disclosed a suprasellar heterogeneous, mainly cystic, 
1.9 × 2 × 1.9 cm mass compressing and displacing the optic 
chiasm and expanding to the third ventricle without 
causing hydrocephalus; these findings were considered to 
be consistent with a craniopharyngioma (Fig. 1A), and he 
was referred for surgery. On initial clinical review, there 
were no typical manifestations consistent with acromegaly.
Investigation
Hormonal investigations revealed hypogonadotropic 
hypogonadism, mildly elevated prolactin levels 
(334 mU/L, reference range 85–325), increased insulin-like 
growth hormone 1 (IGF-1) (365.6 ng/mL, reference range: 
68.1–244.8) and normal thyroid function and cortisol 
reserve. There was no evidence of diabetes insipidus.
Treatment
An endoscopic transsphenoidal resection of the 
suprasellar mass was performed and histopathological 
examination of the removed specimen was diagnostic of 
an adamantinomatous craniopharyngioma WHO grade 1. 
After surgery, the patient’s vision was markedly improved 
and he had diabetes insipidus, adrenocorticotropic 
hormone (ACTH) deficiency, thyroid-stimulating 
hormone (TSH) deficiency and hypogonadotropic 
hypogonadism, requiring desmopressin, hydrocortisone, 
levothyroxine and testosterone replacement therapy. 
Post-operative MRI was reported as showing no residual 
craniopharyngioma tissue. Despite the hypopituitarism, 
Figure 1
(A) Pre-operative T1-weighted images showing an isointense lesion at the 
suprasellar cistern (craniopharyngioma – thick arrow) and an isointense 
to marginally hyperintense lesion related to the right carotid artery 
(pituitary adenoma – thin arrow), with mixed intensity after contrast 
enhancement, (B) post-operative T1-weighted images, before and after 
gadolinium administration, showing the adenoma (thin arrow) and no 
residual craniopharyngioma tissue, (C) pre- and post-contrast-enhanced 
T1-weighted images one year after the initiation of long-acting 
somatostatin analogue treatment showing no craniopharyngioma 
regrowth and stable appearances of the adenoma (thin arrow).
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the patient’s IGF-1 levels remained elevated (369.5 ng/
mL, reference range: 68.1–244.8) and GH was not 
supressed on a 75 g oral glucose tolerance test (nadir: 
1.18 µg/L). Notably, when manifestations of acromegaly 
were discussed at this stage, enlargement of the hands 
and development of more coarse facial features over the 
years were noticed. On further review of the pre-operative 
MRI, a 12 × 4 mm pituitary adenoma close to the right 
carotid artery was noted (Fig.  1); this was also evident 
in the post-operative scan (Fig. 1B). No signs of pituitary 
hyperplasia were demonstrated. During this period, the 
patient was also further investigated for a left lung upper 
lobe consolidation found incidentally in his chest X-ray 
performed in his pre-operative evaluation. Chest computed 
tomography demonstrated a 3 × 2.6 cm endobronchial 
tumour in the left upper lobe and bronchoscopy/fine-
needle aspiration biopsy confirmed the presence of a 
necrotic tumour characterised as squamous cell lung 
carcinoma, T1bN1M0, with no neuroendocrine features; 
immunohistochemistry showed that tumour cells were 
negative for synaptophysin and strongly expressed 
p63. Staging positron emission tomography was not 
consistent with metastatic disease. Cardiac assessment 
had also revealed a non-specific cardiomyopathy 
(NYHA II) associated with mid-ventricular obstruction 
and apical akinesis. Due to the high peri-operative risk, 
surgical management was not considered a safe option 
and radical radiotherapy treatment was offered (55 Gy 
in 20 fractions). For the management of acromegaly, the 
pituitary multidisciplinary team also took into account the 
patient’s co-morbidities and suggested medical treatment 
with long-acting somatostatin analogue, which the 
patient commenced (lanreotide autogel: 90 mg/4 weeks).
Outcome and follow-up
Pituitary MRI one year after the long-acting somatostatin 
analogue initiation showed no craniopharyngioma 
regrowth and stable adenoma appearances (Fig.  1C). 
Somatostatin analogue treatment was well tolerated and 
led to biochemical control of the acromegaly (IGF-1 levels 
within the reference range and random GH <1 µg/L). On 
cardiology review, improvement of the breathlessness was 
documented with exercise tolerance of 300 yards before 
stopping. The patient has regular oncology follow-up and 
no evidence of lung cancer progression.
Discussion
We have presented a very rare case of two co-existent (para)
sellar tumours, an adamantinomatous craniopharyngioma 
and one causing acromegaly. The latter, although not 
histologically proven, was an incidental and rather 
surprising diagnosis pointing out the importance of 
meticulous review of unexpected biochemical findings. 
Retrospective review of the pituitary MRI suggested the 
presence of an adenoma, which is most likely the source 
of GH hypersecretion.
Co-existence of craniopharyngioma and pituitary 
adenoma, either as collision tumours or as two 
clearly distinct lesions, has been very rarely reported. 
The published cases are mostly adamantinomatous 
craniopharyngiomas, whilst the pituitary adenomas are of 
various types, including prolactinomas, non-functioning 
gonadotroph adenomas, a TSH-secreting adenoma and a 
silent ACTH adenoma (4, 5, 6). There are only two reports 
of craniopharyngioma associated with acromegaly due 
to a GH-secreting adenoma, one as collision tumour (7) 
and the second with the diagnosis of craniopharyngioma 
established 18  years after the initial diagnosis of the 
adenoma (with the patient, however, being lost to 
follow-up during this period) (8).
Mutations in exon 3 of the CTNNB1 gene that 
prevent phosphorylation and degradation of β-catenin, 
a component of the adherens junction and a mediator 
of Wnt signalling pathway have been identified in 
adamantinomatous craniopharyngiomas and are possibly 
implicated in their pathogenesis (9). On the other 
hand, pituitary adenomas are monoclonal in origin and 
their pathogenesis is complex and still unclear: genetic 
mutations and epigenetic modifications resulting in 
abnormal cell cycle regulation, defects in signalling 
pathways or loss of tumour suppressor factors have 
been proposed as possible underlying mechanisms (10). 
An aetiological link between these two entities seems 
unlikely and their co-existence in our patient may be 
entirely co-incidental.
The impact of GH excess on the evolution of 
craniopharyngioma cannot be excluded. Strong IGF-1 
receptor expression has been demonstrated in cell 
lines and paraffin-embedded material in a subset of 
craniopharyngiomas; in this group, treatment of cells with 
an IGF-1 receptor inhibitor was associated with decreased 
Akt phosphorylation and growth arrest suggesting that 
the IGF-1 receptor may promote the proliferation of 
craniopharyngioma cells (11).
Furthermore, the GH–IGF axis regulates cell 
proliferation, differentiation, angiogenesis, motility, and 
apoptosis and may contribute to cancer development 
and progression (12). A variety of malignancies have 
been described in association with acromegaly and two 
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recent meta-analyses have demonstrated increased risk of 
colon and thyroid neoplasms in these patients (13, 14). 
Interestingly, over-expression of IGF-1 receptors has been 
suggested in squamous cell lung carcinoma, and this has 
been related with poor prognosis (15).
In our patient, medical treatment of acromegaly 
was considered to be the most pragmatic approach and 
proved to be beneficial for the control of the disease. 
Successful management of the GH hypersecretion was 
also deemed vital given the presence of other tumours 
(craniopharyngioma and lung cancer).
Our case is characterised by a very rare presentation 
of unexpected dual pituitary pathology and highlights 
challenges in its diagnosis and management, particularly, 
in a patient with co-existent lung malignancy.
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